Gossamer Bio, Inc., a late-stage clinical biopharmaceutical company, will present at the Cantor Global Healthcare Conference on September 3rd at 9:10 AM ET. The company will participate in a fireside chat and one-on-one meetings to discuss their work on developing seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250829692001) on August 29, 2025, and is solely responsible for the information contained therein.